- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00600002
Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma
A Phase I Clinical Trial of GM-CSF Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma
The application of immunotherapeutic strategies that target the most potent antigen presenting cell, the dendritic cell (DC), are likely to substantially increase the magnitude of the anti-tumor immune response. Although there are issues of activation state and antigen load, mechanisms to increase the number of DCs available to the immune system are among the first steps in development of affective DC based immunotherapeutic strategies. The Central Hypothesis of our study is: Administration of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) to patients with pancreatic adenocarcinoma will result in enhance recruitment of DCs to the sentinel lymph node, into the peripheral blood, and/or tumor site. We propose performing a phase I, dose escalation, clinical trial of systemic and intra-tumoral GM-CSF administration for the treatment of pancreatic adenocarcinoma. This trial will be designed to assess toxicity and immunologic effects, principally dendritic cell recruitment. Patients with resectable pancreatic adenocarcinoma by clinical staging criteria will be eligible for enrollment.
The trial we propose is a phase I clinical trial of the addition of GM-CSF as a biological adjuvant to standard care for patients with potentially resectable pancreatic adenocarcinoma.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Orange, California, United States, 92868
- Chao Family Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have histological proven adenocarcinoma of the pancreas with potentially resectable disease based upon clinical staging.
- Expected survival must be greater than three (3) months.
- A Karnofsky Performance Status (KPS) must be 70 or greater.
- Patients must be >18 years of age. Because Leukine® is a "Pregnancy Category C" drug, female patients must be not be lactating and must be surgically sterile (via hysterectomy or bilateral tubal ligation), postmenopausal, or using acceptable methods of contraception if they are of child bearing potential. Female patients of childbearing potential must also have a negative serum pregnancy test.
- Patients must be able to understand and sign an informed consent form, which must comply with U.S. regulations (U.S. 21 Code of Federal Regulations (CFR) 50) and International Conference on Harmonisation (ICH) guidelines. Availability of alternative curative treatment must be fully explained to the patient and documented in the informed consent form.
- Eligible patients must meet the following laboratory parameters:
- White blood cell (WBC) >3,000/mm3
- Platelets >100,000/mm3
- Hct >33% or Hgb >10.5 gm/dL
- Prothrombin time (PT) within 3 seconds of control
- Serum creatinine <1.5 mg/dL
- Serum calcium <11.0 mg/dL
- Serum Amylase < 2 times the upper limit of normal
- Negative HIV-Ag and HIV-Ab
Exclusion Criteria:
- Patients who have undergone previous treatment with a biological response modifier (interferons, interleukins) or prior immunotherapy within four (4) weeks of study enrollment.
- Patients currently requiring corticosteroids, under immune suppression for any reason including an organ allograft.
- Patients with known contraindications to analgesia or endoscopy.
- Patients with unstable cardiovascular disease (Class IV cardiovascular disease according to the New York Heart Association's functional criteria).
- Patients with any acute or chronic illness as judged clinically significant by the Investigators.
- Patients who have received prior chemotherapy or radiation therapy to the thorax within four (4) weeks of enrollment.
- Prior surgery within 30 days of execution of the informed consent form.
- Persistent fever greater than 39 degrees Celsius unless clinical assessment attributes the etiology to be tumor.
- Primary malignancy (present or remote) of sites other than the pancreas, except for the basal cell epithelioma of the skin.
- Use of investigational drugs within 30 days of execution of the informed consent form.
- Clinically significant (symptomatic) third space fluid collection (i.e.: ascites, pleural effusion).
- Patients with a diagnosis of an autoimmune state, or any psychiatric illness that in the opinion of the Investigators would compromise treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GM-CSF
Cohort 1: 50 ug/m2 given Intravenous.
Cohort 2: 150 ug/m2 given Intravenous.
Cohort 3: 250 ug/m2 given Intravenous.
Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral.
Cohort 5: 50 ug/m2 given Intra-tumoral.
Cohort 6: 150 ug/m2 given Intra-tumoral.
Cohort 7: 250 ug/m2 given Intra-tumoral.
|
Cohort 1: 50 ug/m2 given Intravenous.
Cohort 2: 150 ug/m2 given Intravenous.
Cohort 3: 250 ug/m2 given Intravenous.
Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral.
Cohort 5: 50 ug/m2 given Intra-tumoral.
Cohort 6: 150 ug/m2 given Intra-tumoral.
Cohort 7: 250 ug/m2 given Intra-tumoral.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate toxicity, dendritic cell recruitment, and immune parameters
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate patient survival
Time Frame: 2 years
|
2 years
|
Evaluate progression free survival
Time Frame: 2 years
|
2 years
|
Evaluate time to treatment failure
Time Frame: 2 years
|
2 years
|
Evaluate quality of life
Time Frame: 2 years
|
2 years
|
Evaluate biochemical markers
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Edward L Nelson, M.D., Chao Family Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UCI 02-69
- 2003-2972 (Other Identifier: University of California, Irvine)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of NebraskaNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
National Cancer Institute (NCI)CompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of UtahNovartis PharmaceuticalsRecruitingMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
Shanghai Zhongshan HospitalFudan UniversityNot yet recruitingPancreatic Cancer Stage III | Pancreatic Cancer, Stage IB | Pancreatic Cancer, Stage IIA | Pancreatic Cancer, Stage IIBChina
-
University of Wisconsin, MadisonCompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Fudan UniversityUnknownStage ⅠA Pancreatic Cancer | Stage ⅠB Pancreatic Cancer | Stage ⅡA Pancreatic Cancer | Stage ⅡB Pancreatic CancerChina
Clinical Trials on GM-CSF
-
Vietnam National UniversityCompleted
-
Memorial Sloan Kettering Cancer CenterNo longer available
-
Nationwide Children's HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingPediatric Sepsis-induced Multiple Organ Dysfunction SyndromeUnited States
-
Eastern Cooperative Oncology GroupCompletedAdult Patients (Over 55) With Acute Non-Lymphocytic Leukemia
-
University Hospital TuebingenCompletedMalignant MelanomaGermany
-
San Antonio Military Medical CenterNuGenerex Immuno-Oncology; Norwell, Inc.CompletedBreast CancerUnited States, Germany, Greece
-
Radboud University Medical CenterCompletedThe Effects of Immunostimulation With GM-CSF or IFN-y on Immunoparalysis Following Human EndotoxemiaSepsis | Inflammation | Endotoxemia | Multi Organ Dysfunction SyndromeNetherlands
-
Xinhua Hospital, Shanghai Jiao Tong University...UnknownLymphoma | Acute Myeloid Leukemia | Neuroblastoma | Retinoblastoma | Hepatoblastoma | Acute Lymphoid LeukemiaChina
-
Centre for Endocrinology and Reproductive Medicine...Completed
-
Marker Therapeutics, Inc.TerminatedOvarian Cancer | Platinum Sensitive Ovarian CancerUnited States